Eric Yu
Overview
Explore the profile of Eric Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
541
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Somerville E, James A, Beetz C, Schwieger R, Barrel G, Kandaswamy K, et al.
Ann Neurol
. 2025 Mar;
PMID: 40022584
GBA1 variants and decreased glucocerebrosidase activity are implicated in Parkinson's disease (PD). We investigated the hypothesis that increased levels of glucosylceramide (GlcCer), a main substrate of glucocerebrosidase, are involved in...
2.
Xiong G, Yu E, Heung M, Yang J, Lowe M, Abu-Hilal M
JAAD Int
. 2025 Jan;
19:1-9.
PMID: 39872731
Oral Janus kinase inhibitors (JAKi) are increasingly used in dermatology, rheumatology, gastroenterology, and hematology. While effective, they can cause adverse effects such as acne, nausea, cytopenia, dyslipidemia, and Herpes zoster....
3.
Ngo A, Liu L, Lariviere S, Kebets V, Fett S, Weber C, et al.
bioRxiv
. 2025 Jan;
PMID: 39868179
Temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) is associated with a complex genetic architecture, but the translation from genetic risk factors to brain vulnerability remains unclear. Here, we examined associations...
4.
Dai J, Rayana N, Peng M, Sugali C, Harvey D, Dhamodaran K, et al.
Sci Rep
. 2024 Dec;
14(1):30930.
PMID: 39730553
Pterygium is an ocular disease in which the conjunctival tissue invades the cornea. When the pterygium tissue reaches the pupillary region, the visual function of the patient is affected. Currently,...
5.
Hedquist A, Yu E, Hamed P, Orav E, Frakt A, Tsai T
JAMA Health Forum
. 2024 Nov;
5(11):e243536.
PMID: 39514195
No abstract available.
6.
Senkevich K, Parlar S, Chantereault C, Yu E, Ahmad J, Ruskey J, et al.
NPJ Parkinsons Dis
. 2024 Oct;
10(1):201.
PMID: 39455605
Previous studies have established that rare biallelic SYNJ1 mutations cause autosomal recessive parkinsonism and Parkinson's disease (PD). We analyzed 8165 PD cases, 818 early-onset-PD (EOPD, < 50 years) and 70,363...
7.
Somerville E, James A, Beetz C, Schwieger R, Barrel G, Kandaswamy K, et al.
medRxiv
. 2024 Oct;
PMID: 39371176
variants and decreased glucocerebrosidase (GCase) activity are implicated in Parkinson's disease (PD). We investigated the hypothesis that increased levels of glucosylceramide (GlcCer), one of GCase main substrates, are involved in...
8.
Sosero Y, Bandres-Ciga S, Ferwerda B, Tocino M, Belloso D, Gomez-Garre P, et al.
Mov Disord
. 2024 Aug;
39(10):1773-1783.
PMID: 39132902
Background: Levodopa-induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a...
9.
Somerville E, Krohn L, Senkevich K, Yu E, Ahmad J, Asayesh F, et al.
Res Sq
. 2024 Jun;
PMID: 38883744
One of the most common genetic risk factors for Parkinson's disease (PD) are variants in , which encodes the lysosomal enzyme glucocerebrosidase (GCase). GCase deficiency has been associated with an...
10.
Senkevich K, Parlar S, Chantereault C, Yu E, Ahmad J, Ruskey J, et al.
medRxiv
. 2024 Jun;
PMID: 38853950
Previous studies have suggested that rare biallelic mutations may cause autosomal recessive parkinsonism and Parkinson's disease (PD). Our study explored the impact of rare variants in non-familial settings, including 8,165...